financetom
Business
financetom
/
Business
/
E3 Lithium, Pure Lithium Provide Results from Phase 1 of Lithium Metal Battery Joint Development Agreement
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
E3 Lithium, Pure Lithium Provide Results from Phase 1 of Lithium Metal Battery Joint Development Agreement
May 26, 2025 12:28 PM

08:51 AM EDT, 05/22/2025 (MT Newswires) -- E3 Lithium ( EEMMF ) reported Thursday initial results from the battery cells manufactured under its joint development agreement with Pure Lithium.

Results from the battery cells -- which use E3 Lithium's ( EEMMF ) brines and direct lithium extraction technology and Pure Lithium's extraction and battery technology -- showed that the various E3 brine streams all achieved a very purity level of over 99.9% pure lithium metal as tested by ICP-OES analysis. The cell performance tests showed that all cells achieved over 500 cycles to date while retaining 80% of its capacity. The charge and discharge tests were conducted at a 1C:1D ratio, one hour charge time and one hour discharge time.

"These results confirm that E3's lithium concentrate can produce battery-ready lithium metal anodes using Pure Lithium's technology," said Chris Doornbos, President and CEO of E3 Lithium ( EEMMF ). "We are very encouraged by the results, and I am excited by the prospect of developing a local lithium battery supply chain in collaboration with Pure Lithium."

E3's share price fell 1.8% on Wednesday to $0.55 on the TSXV.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FDA declines to approve Atara Biotherapeutics' cancer therapy
US FDA declines to approve Atara Biotherapeutics' cancer therapy
Jan 16, 2025
Jan 16 (Reuters) - The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' ( ATRA ) cancer therapy, chemically called tabelecleucel. The company was seeking approval for the therapy to treat patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). ...
Market Chatter: Carlyle Mulls Sale of Calastone
Market Chatter: Carlyle Mulls Sale of Calastone
Jan 16, 2025
08:32 AM EST, 01/16/2025 (MT Newswires) -- Carlyle Group ( CG ) is working with Barclays ( JJCTF ) to explore a sale of Calastone, a London-based funds network and data business, Reuters reported Thursday, citing four people familiar with the matter. While the process is in the early stages, Carlyle is anticipated to hold an auction before the summer,...
Nintendo says Switch 2 will be released in 2025
Nintendo says Switch 2 will be released in 2025
Jan 16, 2025
TOKYO (Reuters) -Japanese gaming company Nintendo will launch the Switch 2 console, successor to its hit Switch device, this year, it said on Thursday. The Kyoto-based company did not release pricing for the new device and said it would provide more details at a Nintendo Direct event on April 2. The company has said that existing Switch software will be...
Target's Holiday Sales Surge 2.8%: Digital Growth And Black Friday Wins Drive Results
Target's Holiday Sales Surge 2.8%: Digital Growth And Black Friday Wins Drive Results
Jan 16, 2025
Target Corp ( TGT ) reported a 2.8% increase in holiday sales during the November and December period. The company saw comparable sales rise 2% and solid sales during the Black Friday and Cyber Monday promotions. The increase was fueled by a nearly 3% rise in traffic, positively impacting both in-store and online channels. Particularly notable was the nearly 9%...
Copyright 2023-2026 - www.financetom.com All Rights Reserved